Results 61 to 70 of about 886,923 (294)
Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute +17 more
wiley +1 more source
Background: Individuals who are victimized and exploited by the heinous crimes of human trafficking (HT) access healthcare during their exploitation, yet gaps in education on HT content exist in prelicensure nursing programs.
Debra McWilliams +2 more
doaj +1 more source
The LINC01116 long noncoding RNA is induced by hypoxia and associated with poor prognosis and high recurrence rates in two cohorts of lung adenocarcinoma patients. Here, we demonstrate that besides its expression in cancer cells, LINC01116 is markedly expressed in lymphatic endothelial cells of the tumor stroma in which it participates in hypoxia ...
Marine Gautier‐Isola +12 more
wiley +1 more source
Background: Oxygen therapy is a long-standing, life-saving intervention, but its administration requires careful management to maximize benefits and reduce potential harm. Aim: This study assessed the knowledge, attitudes, practices, and barriers related
Iddrisu Mohammed Sisala +5 more
doaj +1 more source
Commentary on Spilsbury K, Petherick E, Cullum N, Nelson A, Nixon J & Mason S (2008) The role and potential contribution of clinical research nurses to clinical trials.Journal of Clinical Nursing17, 549–557 [PDF]
Claire M. Rickard, Brigit Roberts
openalex +1 more source
A qualitative content analysis of nurses' perceptions about readiness to manage intimate partner violence [PDF]
Erica Briones‐Vozmediano +6 more
openalex +1 more source
A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti +3 more
wiley +1 more source

